Nkarta, Inc.

Nkarta, Inc. (NKTX) priced its initial public offering on Jul 13, 2020 at $18.00 per share, above its $16.00–$17.00 range, raising $252M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $547.7M. TD Cowen was lead-left underwriter, joined by Evercore ISI, Stifel and Mizuho. O’Melveny & Myers advised the company and A&O Shearman advised the underwriters.

Nkarta, Inc. is a biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for cancer. Its NK cell engineering platform adds chimeric antigen receptors to NK cells and includes technologies to produce abundant cells and improve their persistence.

Status

IPO

Ticker

NKTX

Exchange

Nasdaq Global Select

Priced

Jul 13, 2020

IPO price

$18.00

Price range

$16.00–$17.00

Raised

$252M

Market cap at IPO price

$547.7M

First filed

Jun 19, 2020

Underwriters

TD Cowen, Evercore ISI, Stifel and Mizuho

Company counsel

O’Melveny & Myers

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.